Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results

Stifel Reiterates Buy Rating on Dianthus Therapeutics (DNTH)

March 12, 2025 7:39 AM EDT

Stifel analyst Alex Thompson reiterated a Buy rating and $52.00 price target on Dianthus Therapeutics (NASDAQ: DNTH)

The analyst comments "We are reiterating our Buy Rating on DNTH following their 4Q24 update. DNTH remains one of our favorite ideas for 2025 based on our broader view... More